1.Belyalov F.I. Treatment of diseases in conditions of comorbidity. 10th ed. Moscow: GEOTAR-Media; 2016. (In Russ.) [БеляловФ.И. Лечениеболезнейвусловияхкоморбидности. Изд. 10-е. Москва: ГЭОТАР-Медиа; 2016].2.Ишемическая болезнь сердца и нарушение функции почек Фарид Исмагильевич Белялов3.Sedlis S.P., Jurkovitz C.T., Hartigan P.M., et al. Optimal medical therapy with or without percutaneous coronary intervention for patients with stable coronary artery disease and chronic kidney disease. Am J Cardiol. 2009; 104: 1647-53. 4.United States Renal Data System. Renal Data System Chapter 4: Cardiovascular Disease in Patients With CKD. Am J Kidn Dis. 2016;67(3):S49-S56.5.Tonelli M., MuntnerP., Lloyd A., et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet. 2012;380(9844): 807-14.6.Gottlieb S.S., McCarter R.J., Vogel R.A. et al. Effect of Beta-Blockade on Mortality among High-Risk and Low-Risk Patients after Myocardial Infarction. N Engl J Med .1998;339:489-97. 7.Fleet J.L., Weir M.A., McArthur E. et al. Kidney Function and Population-Based Outcomes of Initiating Oral Atenolol Versus Metoprolol Tartrate in Older Adults. American Journal of Kidney Diseases. 2014;64:883-91